Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Company

Grand Pharmaceutical Group

Tracked across 4 events · 24 articles · First seen Apr 09, 2026 · Last active May 14, 2026

Sentiment
25
Attention
4
Events
4
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 30
Regulatory
Impact: Grand Pharmaceutical Group, a Chinese company, achieved a rare win in Washington as CFIUS rejected FastWave's request for a national security review of its investment. This allows Grand Pharmaceutical Group to maintain its 40% stake in FastWave.
Apr 09, 2026 · 6 articles
4 20
Tech
Impact: GSK plc licensed the Mo-rez drug from Grand Pharmaceutical Group in 2023, indicating a potential future revenue stream for Grand Pharmaceutical Group.
Apr 12, 2026 · 6 articles
4 50
Tech
Impact: Grand Pharmaceutical Group is an investor in Xeltis, and the successful clinical data for aXess™ could enhance the value of their investment.
Apr 21, 2026 · 6 articles
4 0
Business
Impact: Renfu, a condom company selling in China, did not immediately respond to a request for comment regarding the price increases.
Apr 23, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Grand Pharmaceutical Group live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.